Dergiler / Archives of Rheumatology / 2021 / Cilt: 36 - Sayı: 3

Predictors of renal and patient outcomes in anti-neutrophilcytoplasmic antibody-associated vasculitis:Our single-center, tertiary care experience

Sayfa
445–457
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In addition, AAV patients with hypocomplementemia may have a lower remission rate.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to assess the different predictors of renal and patient prognosis in anti-neutrophil cytoplasmic antibodies(ANCA)-associated vasculitis (AAV) patients with and without renal involvement.
📊
Temel Bulgular & Veri:Patients and methods: A total of 79 patients (51 males, 28 females; mean age: 57.3±14.2 years; range, 18 to 71 years) with AAV between January2006 and November 2019 were retrospectively analyzed.
💡
Sonuç & Katkı:In addition, AAV patients with hypocomplementemia may have a lower remission rate.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: This study aims to assess the different predictors of renal and patient prognosis in anti-neutrophil cytoplasmic antibodies(ANCA)-associated vasculitis (AAV) patients with and without renal involvement. Patients and methods: A total of 79 patients (51 males, 28 females; mean age: 57.3±14.2 years; range, 18 to 71 years) with AAV between January2006 and November 2019 were retrospectively analyzed. Demographic and laboratory data including the complement 3 (C3) serum levels andrenal biopsy findings were extracted from the electronic and printed medical records of the hospital registry. Survival, renal survival, remission, andrelapse outcomes were analyzed. Results: A total of 35% of the patients with renal involvement progressed to end-stage renal disease (ESRD). The dialysis requirement at the time ofadmission (hazard ratio [HR]: 21.95 [2.93-164.22]; p=0.003), estimated glomerular filtration rate (eGFR) (HR: 0.97 [0.94-0.99]; p=0.024) and Five-FactorScore (FFS) ≥2 at the time of diagnosis (HR: 3.59 [1.08-11.94]; p=0.037) were the predictors of ESRD. The five-year patient survival rate was 87.1%.The only predictor of mortality was age (HR: 1.07 [1.01-1.14]; p=0.024). The patients with hypocomplementemia (22%) had a lower remission rate(p=0.049), FFS ≥2 at the time of diagnosis (p=0.026), and higher levels of hematuria (p=0.004) and proteinuria (p=0.037). The FFS ≥2 at the time ofdiagnosis was an independent predictor of relapse (HR: 8.9 [1.02-77.36]; p=0.047). Conclusion: Our study suggests that the baseline renal function and FFS ≥2 at the time of diagnosis are the major prognostic factors for progressionto ESRD in AAV patients. In addition, AAV patients with hypocomplementemia may have a lower remission rate.

🔖

Bu Makaleye Atıf Yap

TORAMAN, A., GÜNDÜZ, Ö. S. (2022). Predictors of renal and patient outcomes in anti-neutrophilcytoplasmic antibody-associated vasculitis:Our single-center, tertiary care experience. Archives of Rheumatology, Cilt: 36 - Sayı: 3, 445–457. https://ajindex.com/articles/447996

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11
  2. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al. Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int 2002;61:80-9
  3. Schilder AM. Wegener's Granulomatosis vasculitis and granuloma. Autoimmun Rev 2010;9:483-7
  4. Villiger PM, Guillevin L. Microscopic polyangiitis: Clinical presentation. Autoimmun Rev 2010;9:812-9
  5. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: A systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-10
  6. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94
  7. Moiseev S, Novikov P, Jayne D, Mukhin N. End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant 2017;32:248-53
  8. Diaz-Crespo F, Villacorta J, Acevedo M, Cavero T, Guerrero C, García Díaz E, et al. The predictive value of kidney biopsy in renal vasculitis: A multicenter cohort study. Hum Pathol 2016;52:119-27
  9. Córdova-Sánchez BM, Mejía-Vilet JM, MoralesBuenrostro LE, Loyola-Rodríguez G, UribeUribe NO, Correa-Rotter R. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol 2016;35:1805-16
  10. Augusto JF, Langs V, Demiselle J, Lavigne C, Brilland B, Duveau A, et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PLoS One 2016;11:e0158871
  11. Hilhorst M, van Paassen P, van Rie H, Bijnens N, Heerings-Rewinkel P, van Breda Vriesman P, et al. Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2017;32:1302-13
  12. Chen M, Jayne DRW, Zhao MH. Complement in ANCAassociated vasculitis: Mechanisms and implications for management. Nat Rev Nephrol 2017;13:359-67
  13. Kallenberg CG, Stegeman CA, Abdulahad WH, Heeringa P. Pathogenesis of ANCA-associated vasculitis: New possibilities for intervention. Am J Kidney Dis 2013;62:1176-87
  14. Moiseev S, Lee JM, Zykova A, Bulanov N, Novikov P,